<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044768</url>
  </required_header>
  <id_info>
    <org_study_id>ADP 0044-002</org_study_id>
    <nct_id>NCT04044768</nct_id>
  </id_info>
  <brief_title>Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma</brief_title>
  <official_title>A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptimmune</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of genetically engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or
      inoperable (advanced) Synovial Sarcoma or MRCLS who have received prior chemotherapy and
      whose tumor expresses the MAGE-A4 tumor antigen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2034</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Overall Response Rate (ORR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>2.5 years</time_frame>
    <description>Determine if treatment with ADP-A2M4 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of ADP-A2M4 through measurement of Replication -competent Retrovirus in genetically engineered T-cells</measure>
    <time_frame>2.5 years</time_frame>
    <description>Evaluation of RCL using PCR -based assay in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of T-cell clonality and insertional oncogenesis in peripheral blood mononuclear cells (PBMCs).</measure>
    <time_frame>2.5 years</time_frame>
    <description>Measurement of T-cell clonality and insertional oncogenesis in peripheral blood mononuclear cells (PBMCs )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Best overall response (BOR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>BOR is per RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>2.5 years</time_frame>
    <description>For patients who are observed to respond to ADP-A2M4, the DoR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2.5 years</time_frame>
    <description>PFS is assessed from date of infusion of ADP-A2M4 up until the date of disease progression per RECIST v1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>15 years</time_frame>
    <description>OS is assessed from date of infusion of ADP-A2M4 up until the date of patient death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quantitation of genetically engineered T-cells in PBMCs by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Quantitation of genetically engineered T-cells in PBMCs by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs</measure>
    <time_frame>2.5 years</time_frame>
    <description>Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invitro diagnostic (IVD) assay for screening</measure>
    <time_frame>2.5 years</time_frame>
    <description>Development and validation of the MAGE-A4 antigen expression companion diagnostic assay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Synovial Sarcoma</condition>
  <condition>Myxoid Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Autologous genetically modified ADP-A2M4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ADP-A2M4</intervention_name>
    <description>Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion</description>
    <arm_group_label>Autologous genetically modified ADP-A2M4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Age ≥16 and &lt;=75 years

          -  Diagnosis of advanced synovial sarcoma or myxoid liposarcoma / myxoid round cell
             liposarcoma confirmed by cytogenetics.

          -  Previously received either an anthracycline or ifosfamide containing regimen.

          -  Measurable disease according to RECIST v1.1.

          -  HLA-A*02 positive

          -  Tumor shows MAGE-A4 expression confirmed by central laboratory.

          -  ECOG Performance Status of 0 or1.

          -  Left ventricular ejection fraction (LVEF) ≥40%.

        Note: other protocol defined Inclusion criteria may apply

        Key Exclusion Criteria:

          -  HLA-A*02:05 in either allele; HLA-A*02:07 or any A*02 null allele as the sole HLA-A*02
             allele

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to fludarabine, cyclophosphamide or other agents used in the study.

          -  History of autoimmune or immune mediated disease

          -  Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases.

          -  Other prior malignancy that is not considered by the Investigator to be in complete
             remission

          -  Clinically significant cardiovascular disease

          -  Uncontrolled intercurrent illness

          -  Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C
             virus, or human T cell leukemia virus

          -  Pregnant or breastfeeding

        Note: other protocol defined Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deijka Aruajo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center; Houston TX 77030</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deijka Aruajo, MD</last_name>
    <phone>713-792-3626</phone>
    <email>daraujo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hripsime Martirosyan</last_name>
      <phone>626-218-2835</phone>
      <email>hmartirosyan@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Cara Nolan</last_name>
      <phone>626-218-2341</phone>
      <email>canolan@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Warren Chow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria S Ahern</last_name>
      <phone>650-725-6413</phone>
      <email>mahern@stanfird.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Newbold</last_name>
      <phone>720-848-0653</phone>
      <email>coutney.newbold@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Breelyn Wilky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Althuis-Brown</last_name>
      <email>althuis-brown.margot@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Attia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Gorham</last_name>
      <phone>813-745-4027</phone>
      <email>yvonne.gorham@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas McWilliams</last_name>
      <phone>312-695-1334</phone>
      <email>nicholas.mcwilliams@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Bernstein</last_name>
      <phone>240-760-6189</phone>
      <email>bernsted@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>John Glod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Solomon</last_name>
      <phone>617-582-7503</phone>
      <email>ssolomon1@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Field</last_name>
      <phone>617-632-6708</phone>
      <email>julie_field@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine Thornton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Harvey</last_name>
      <email>harveypj@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Schuetze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nic Perry</last_name>
      <phone>314-273-2831</phone>
      <email>nperry@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Olmas</last_name>
      <phone>212-342-5162</phone>
      <email>lo2345@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Martin</last_name>
      <phone>646-888-4339</phone>
      <email>martinn@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Sandra D'Angelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Liebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Dumont</last_name>
      <phone>615-936-5173</phone>
      <email>anna.dumont@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Vicki Keedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamatha Hamumanthaiah</last_name>
      <email>mhanumanthaiah@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Deijka Aruajo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Moore</last_name>
      <phone>206-606-6424</phone>
      <email>romoore@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Michael Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aileen Trang</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>7754</phone_ext>
      <email>aileen.trang@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Albiruni G Razak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer (CLCC) - Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Louchet</last_name>
      <phone>+33547306088</phone>
      <email>s.louchet@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maud Toulmonde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Linard</last_name>
      <email>pauline.linard@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jeans-Yves Blay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Center</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anais Pinto</last_name>
      <phone>+33142115833</phone>
      <email>anaispinto@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Axel LeCesne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>119-129</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Soler</last_name>
      <email>msoler@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Claudia Valverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Start Madrid-FJD, Fundación Jimѐnez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Armellini</last_name>
      <email>Adriana.Armellini@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Victor Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Del Mar Torres</last_name>
      <email>mtorser@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier Martin-Broto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLH Cancer Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Taylor</last_name>
      <email>sarah.tayloe83@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sandra Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shweta Vyas</last_name>
      <phone>+44 (0) 161 918 2323</phone>
      <email>Shweta.vyas@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Fiona Thistlethwaite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>T Cell Therapy</keyword>
  <keyword>SPEAR T Cell</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>MRCLS</keyword>
  <keyword>MAGE A-4</keyword>
  <keyword>Immuno-oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

